This was the stock's second consecutive day of losses.

Regeneron Pharmaceuticals (NASDAQ:REGN) has reportedly declined to submit a higher bid for 23andMe (OTC:MEHCQ) after a ...

The agency cleared CSL’s hereditary angioedema drug days after “resource constraints” delayed a rival medicine. Elsewhere, ...

The severe asthma treatment market is experiencing robust expansion, driven by rising disease prevalence, improved diagnostic approaches, and breakthrough therapeutic developments from key ...

Regeneron Pharmaceuticals was outbid in its effort to buy 23andMe by a nonprofit led by the bankrupt genetics testing company’s co-founder. California-based TTAM Research Institute, led by Anne ...

Findings that U.S. companies can sue foreign rivals despite limited business operations in the country could dissuade drug ...

Genetic testing firm 23andMe has been fined £2.31 million by the UK's data protection watchdog for "serious security failings ...

The debate between CAR T-cell therapy and bispecific antibodies is not a rivalry but a question of sequencing, ...

DNA testing firm 23andMe has been fined £2.31m by a UK watchdog over a data breach in 2023 which affected thousands of people ...

In a recent investigation we took a hard look at the cybersecurity practices of major direct-to-consumer DNA testing ...

The ICO has fined 23andMe £2.31 million due to its failures in responding to a 2023 data breach. The UK's data protection watchdog has fined DNA testing company 23andMe £2.31 million for failing to ...